Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (A11) rabbit mAb
Human Erk1 and Erk2 Ser/Thr kinases share 84% sequence identity and nearly all functions. These MAP kinases are activated in response to mitogens and growth factors as part of the Ras-Raf-MEK-ERK signal transduction cascade(1-3). This pathway regulates cell survival, differentiation, adhesion, cell cycle progression, and many other cellular processes. Upon phosphorylation, Erk1/2 translocate to the nucleus to activate transcription factors including c-Fos, Elk1, Ets1, and SP-1 (4,5). There are more than 175 known cytoplasmic and nuclear substrates of Erk1/2. The Erk1/2 cascade is upregulated in many human cancers, even when oncogenic mutations are not found. Multiple small-molecule inhibitors of Erk1/2 have been developed, including ones targeting the ATP-binding site either competitively or irreversibly (6).
|Applications||Flow Cytometry, WB|
|Validated Reactivity||Human, Mouse|
|Cross Reactivity||Predicted to work with mouse, rat, and other homologues.|
|Immunogen||A synthetic phospho-peptide corresponding to residues surrounding Thr202/Tyr204 of human phospho Erk1/2.|
|Formulation||1X PBS, 0.02% NaN3, 50% Glycerol, 0.1% BSA|
|Recommended Usage||1µg/mL – 0.001µg/mL. It is recommended that the reagent be titrated for optimal performance for each application. See product image legends for additional information.|
|Pseudonyms||Mitogen-activated protein kinase 3, MAPK3, ERK2, p44-MAPK, PRKM3, Mitogen-activated protein kinase 1, MAPK1, ERK1, p42-MAPK, PRKM1, PRKM2|
|Uniprot ID||P27361 P28482|
|References||1. Blagoev B, et al., 2003, Nat Biotechnol, 21:315-318.
2. Thelemann A. et al, 2005, Mol Cell Proteomics, 4:356-376.
3. Morandell S, et al., 2008, Proteomics, 8:4383-4401.
4. Ramos JW, 2008, Biochem Cell Biol, 40:2707-2719.
5. Nakano H, et al., 1998, Proc Natl Acad Sci USA, 104:19837-19842.
6. Roskoski Jr R, 2012, Pharmacol Res, 66:105-143.